nach oben

Archives of Gynecology and Obstetrics

Erschienen in:

01.02.2009 | Original Article

Inhibition of multi-drug resistance of ovarian carcinoma by small interfering RNA targeting to MRP2 gene

verfasst von: Jia-jia Ma, Bi-liang Chen, Xiao-yan Xin

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 2/2009

Einloggen, um Zugang zu erhalten

Abstract

Aims

To investigate the inhibiting mechanism of multi-drug resistance (MDR) using expression vectors of short hairpin RNA (shRNA) in a MDR human ovarian cancer cell line (A2780/cp70).

Methods

Two shRNA expression vectors were constructed and introduced into A2780/cp70 cells. Expression of MRP2 mRNA was assessed by RT-PCR, and Mrp2 expression was determined by Western blot and immunocytochemistry. Apoptosis and sensitization of the cells to cisplatinum were quantified by flow cytometry and methyl-thiazol-tetrazolium (MTT) assays. Cellular cisplatinum accumulation was assayed by laser scanning confocal microscopy (LSCM).

Results

In A2780/cp70 cells transfected with MRP2-A and MRP2-B shRNA expression vectors, RT-PCR showed that MRP2 mRNA expression was reduced by 41.8% (P < 0.05), 30.9% (P < 0.01) (transient transfection) and 39.6% (P < 0.05), 29.4% (P < 0.01) (stable transfection), respectively. Western blot and immunocytochemistry showed that Mrp2 expression was significantly and specifically inhibited. Resistance against cisplatinum was decreased from 173- to 119-fold (P < 0.05), 64-fold (P < 0.01) (transient transfection) and to 117-fold (P < 0.05), 60-fold (P < 0.01) (stable transfection). Furthermore, shRNA vectors significantly enhanced the cellular cisplatinum accumulation. The combination of shRNA vectors and cisplatinum significantly induced the apoptosis of cells.

Conclusions

shRNA expression vectors effectively reduce MRP2 expression and can restore the sensitivity of drug-resistant cancer cells to conventional chemotherapeutic agents.

Pardridge WM (2004) Intravenous, non viral RN gene therapy of brain cancer [J]. Expert Opin Biol Ther 4(7):1103–1113PubMedCrossRef

Kartner N, Shales M, Riordan JR, Ling V (1983) Daunorubicin-resistant Chinese hamster ovary cells expressing multidrug resistance and a cell-surface P-glycoprotein. Cancer Res 43:4413–4419PubMed

Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC et al (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258:1650–1654PubMedCrossRef

Borst P, Evers R, Kool M, Wijnholds J (2000) A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 92:1295–1302PubMedCrossRef

Taniguchi K, Wada M, Kohno K, Nakamura T, Kawabe T, Kawakami M et al (1996) A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res 56:4124–4129PubMed

Ozols RF (1985) Pharmacologic reversal of drug resistance in ovarian cancer. Semin Oncol 12:7–11PubMed

Kool M, de Haas M, Scheffer GL, Scheper RJ, van Eijk MJ, Juijn JA et al (1997) Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 57:3537–3547PubMed

Liedert B, Materna V, Schadendorf D, Thomale J, Lage H (2003) Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin. J Invest Dermatol 121:172–176PubMedCrossRef

Cui Y, Konig J, Buchholz JK, Spring H, Leier I, Keppler D (1999) Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol 55:929–937PubMed

10.

Milhavet O, Gary DS, Mattson MP (2003) RNA interference in biology and medicine[J]. Pharmacol Rev 55(4):629–648PubMedCrossRef

11.

Scherr M, Battmer K, Schuhheis B et al (2005) Stable RNA interference (RNAi) and an option for anti-bcrabl therapy[J]. Gene Ther 12(1):l2–2 lCrossRef

12.

Wohlbold L, van der Kuip H, Miething C et al (2003) Inhibition of berabl gene expression by small interfering RNA sensitizes for imatinib mesylate (ST1571) [J]. Blood 102(6):2236–2239PubMedCrossRef

13.

Hannon GJ (2002) RNA interference [J]. Nature 418(6894):244–251PubMedCrossRef

14.

DaRoeha WD, Otsu K, Teixeira SM et al (2004) Tests of cytoplasmic RNA interferece (RNAi) and construction of a tetracyclineinducible T7 promoter system in Trypanosome cruzi [J]. Mol Biochem Parasitol 133(2):175–186CrossRef

15.

Sui GCH, Soohoo C, Afar EB et al (2002) A DNA vector-based RNAi technology to suppres gene expresion in mammalian cells [J]. PNAS 99:5515–5520PubMedCrossRef

16.

Borkhardt A (2002) Blocking oncogenes in malignant cells by RNA interference—new hope for a highly specific cancer treatment [J]. Cancer Cell 2(2):167–168PubMedCrossRef

17.

Bentires-Alj M, Barbu V, Fillet M et al (2003) NF-KB transcription factor induces drug resistance through MRP2 expression in cancer cells [J]. Oncogene 22:90–97PubMedCrossRef

18.

Hang L, Yang N, Mohamed Hadley A et al (2003) Vector-based RNAi:a novel tool for isoform-specific knock-down of VEGF and anti angiogenesis gene therapy of cancer [J]. Biochem Biophys Res Commun 303(4):1169–1178CrossRef

19.

Brummelkamp TR, Bernards R, Agami R (2002) Stable suppression of tumorigenicity by virus-mediated RNA interference [J]. Cancer Cell 2(3):243–247PubMedCrossRef

20.

Schaub TP, Kartenbeck J, Konig J, Spring H, Dorsam J, Staehler G et al (1999) Expression of the MRP2 gene-encoded conjugate export pump in human kidney proximal tubules and in renal cell carcinoma. J Am Soc Nephrol 10:1159–1169PubMed

21.

Nies AT, Konig J, Pfannschmidt M, Klar E, Hofmann WJ, Keppler D (2001) Expression of the multidrug resistance proteins MRP2 and MRP3 in human hepatocellular carcinoma. Int J Cancer 94:492–499PubMedCrossRef

22.

Sandusky GE, Mintze KS, Pratt SE, Dantzig AH (2002) Expression of multidrug resistance-associated protein 2 (MRP2) in normal human tissues and carcinomas using tissue microarrays. Histopathology 41:65–74PubMedCrossRef

23.

Arts HJ, Katsaros D, de Vries EG, Massobrio M, Genta F, Danese S et al (1999) Drug resistance-associated markers P-glycoprotein, multidrug resistanceassociated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma. Clin Cancer Res 5:2798–2805PubMed

24.

Materna V, Pleger J, Hoffmann U, Lage H (2004) RNA expression of MDR1/Pglycoprotein, DNA-topoisomerase I, and MRP2 in ovarian carcinoma patients: correlation with chemotherapeutic response. Gynecol Oncol 94:152–160PubMedCrossRef

25.

Mayer F, Stoop H, Scheffer GL, Scheper R, Oosterhuis JW, Looijenga LH et al (2003) Molecular determinants of treatment response in human germ cell tumors. Clin Cancer Res 9:767–773PubMed

26.

Hu Xiaoqu, Su Fengxi, Qin Li, Jia Weijuan et al (2006) Stable RNA interference of ErbB–2 gene synergistic with epirubicin suppresses breast cancer growth in vitro and in vivo [J]. Biochem Biophys Res Commun 346(3):778–785PubMedCrossRef

Titel: Inhibition of multi-drug resistance of ovarian carcinoma by small interfering RNA targeting to MRP2 gene
verfasst von: Jia-jia Ma
Bi-liang Chen
Xiao-yan Xin
Publikationsdatum: 01.02.2009
Verlag: Springer-Verlag
Erschienen in: Archives of Gynecology and Obstetrics / Ausgabe 2/2009
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-008-0690-8

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Inhibition of multi-drug resistance of ovarian carcinoma by small interfering RNA targeting to MRP2 gene

Abstract